Colin Drummond1. 1. Professor of Addiction Psychiatry, National Addiction Centre, Institute of Psychiatry, Psychology and Neuroscience, King's College London 4 Windsor Walk, London SE5 8BB, United Kingdom.
The policy maker wants to know who needs addiction treatment and what proportion
of this population should, and do, receive it. The basic principles of needs assessment
for addiction treatment are simple enough. One can calculate the ratio of the number of
people who access treatment divided by the number of people in the population who need
treatment in a given jurisdiction (Drummond et al.,
2005). However, as several articles in this issue point out, producing a
meaningful and practically useful estimate of the treatment access ratio is far from
simple. Having a diagnosis of substance use disorder in a general population survey does
not necessarily equal “need” (Ritter et
al., 2019). Walking through the entrance of an addiction service does not
equal receiving or benefitting from appropriate care (Ritter et al., 2019; Rush et al.,
2019). Measuring and monitoring these events in real time can be costly, time
consuming, and reliant on the quality of the information available and will be more
challenging in resource-poor settings. Further, extrapolating from typical
treatment-seeking populations to smaller subgroups such as youth or indigenous
populations may not be appropriate and will require additional effort as well as
different methodologies (Tremblay et al.,
2019).Nevertheless, it is pleasing to see from these collected articles that the field of
needs-based service planning has developed into a sophisticated science since the
original seminal work by Brian Rush (1990).
Segmenting the in-need population into different severity subgroups—and treatment
into different levels of intensity of care—is a welcome development and provides
a better understanding of which needs are being (or are likely to be) met by which
services. A simplistic model of the ratio of access to prevalence could, in the worst
case, mask an inadequate treatment system that simply provides a lot of people with
suboptimal or ineffective interventions. But congratulations all around on what a great
job we are doing on improving treatment access.The treatment system is a key part of a country’s overall public health response
to substance misuse. The more people that access effective substance misuse treatment,
the more that will recover, thereby reducing demand for substances and the burden of
disease on the wider health system and society. In addition, there will be overall
improved health and quality of life for the individuals receiving effective care.
Indeed, it is possible to model the impact of increasing treatment access on overall
public health (Shield et al., 2014).In an era of global austerity and rising burden of substance misuse, combined with the
development of valuebased health care, it is important to focus limited resources on
achieving the greatest impact. Is there greater value in targeting the large number of
hazardous and harmful drinkers with relatively low-cost interventions with the aim of
reducing more costly harms in the future? Or are the returns on investment likely to be
greater by providing more intensive and expensive treatment to people with alcohol
dependence who are complex “high-need, high-cost” consumers of wider
health care? In an ideal world the answer would be to do all of the above. But limiting
factors will be resources and the feasibility of implementation. Rolling out universal
alcohol screening and brief interventions in primary care is challenging. Equally,
providing intensive specialist interventions for people with complex needs requires
sufficient specialist expertise and a well-developed treatment system. The articles in
this issue remind us that there remain wide differences in treatment access ratios
across the globe. And even in high-resource countries, there can be large differences in
access between regions, localities, and demographic groups.An interesting development, and one that needs-assessment research will need to
assimilate, is in viewing specialist addiction treatment less as a separate system of
care and more as part of the wider health and social care (and criminal justice) system.
In this paradigm, a treatment journey does not begin at the door of the addiction
treatment center but is part of a more comprehensive integrated care pathway, beginning
with identification in primary, acute, or mental health care. The development of
addiction care teams in acute hospitals (Royal College of
Physicians, 2001) and assertive outreach for hard-to-reach populations with
complex needs (Drummond et al., 2017) are two
examples of taking addiction care to the patient, rather than waiting for them to access
conventional addiction services or develop serious illness and die without accessing
addiction treatment at all. A similar model is being applied to the goal of eradication
of hepatitis C (Williams et al., 2018). But this
will require a paradigm shift in both addiction services and the wider health care
system. Our challenge is to measure, evaluate, model, and advocate for such a
transformation, which could bring greater benefits to society as a whole.
Acknowledgments
The author is funded in part by National Institute for Health Research (NIHR)
Biomedical Research Centre for Mental Health at South London and Maudsley NHS
Foundation Trust and King’s College London, as well as the NIHR
Collaborations for Leadership in Applied Health Research and Care South London at
King’s College Hospital NHS Foundation Trust. He is in receipt of an NIHR
Senior Investigator Award.
Authors: Roger Williams; Graeme Alexander; Iain Armstrong; Alastair Baker; Neeraj Bhala; Ginny Camps-Walsh; Matthew E Cramp; Simon de Lusignan; Natalie Day; Anil Dhawan; John Dillon; Colin Drummond; Jessica Dyson; Graham Foster; Ian Gilmore; Mark Hudson; Deirdre Kelly; Andrew Langford; Neil McDougall; Petra Meier; Kieran Moriarty; Philip Newsome; John O'Grady; Rachel Pryke; Liz Rolfe; Peter Rice; Harry Rutter; Nick Sheron; Alison Taylor; Jeremy Thompson; Douglas Thorburn; Julia Verne; John Wass; Andrew Yeoman Journal: Lancet Date: 2017-11-29 Impact factor: 79.321
Authors: Kevin D Shield; Jürgen Rehm; Maximilien X Rehm; Gerrit Gmel; Colin Drummond Journal: BMC Health Serv Res Date: 2014-02-05 Impact factor: 2.655
Authors: Colin Drummond; Helen Gilburt; Tom Burns; Alex Copello; Michael Crawford; Ed Day; Paolo Deluca; Christine Godfrey; Steve Parrott; Abigail Rose; Julia Sinclair; Simon Coulton Journal: Alcohol Alcohol Date: 2017-03-09 Impact factor: 2.826